173 related articles for article (PubMed ID: 37111560)
1. Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy.
Yang Y; Wang Q; Zou H; Chou CK; Chen X
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111560
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide induce response in patients with corticosteroid-resistant or relapsed ITP by upregulating Neuropilin-1 expression.
Yang ZG; Wen RT; Zhang YM; Wu GC; Chen WJ; Wang YF; Weng ZY; Wen SS; Zhang XJ; Guan MH
Int Immunopharmacol; 2019 Jul; 72():437-444. PubMed ID: 31030100
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A.
Chuong PH; Galons H; Voisin J; Zhu J; Righenzi S; Warnet JM; Claude JR; Huynh-Thien D
Int J Immunopharmacol; 1997 May; 19(5):289-96. PubMed ID: 9439767
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood.
Neubert R; Nogueira AC; Neubert D
Arch Toxicol; 1993; 67(1):1-17. PubMed ID: 8452474
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of parenteral nanoemulsions containing thalidomide.
Araújo FA; Kelmann RG; Araújo BV; Finatto RB; Teixeira HF; Koester LS
Eur J Pharm Sci; 2011 Feb; 42(3):238-45. PubMed ID: 21130164
[TBL] [Abstract][Full Text] [Related]
8. TNFR2-expressing CD4
He J; Li R; Chen Y; Hu Y; Chen X
Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
[TBL] [Abstract][Full Text] [Related]
9. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
Chen Y; Jia M; Wang S; Xu S; He N
Front Immunol; 2022; 13():835690. PubMed ID: 35251028
[TBL] [Abstract][Full Text] [Related]
10. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells.
Kampan NC; Madondo MT; McNally OM; Stephens AN; Quinn MA; Plebanski M
Front Immunol; 2017; 8():1482. PubMed ID: 29163543
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
Zou H; Li R; Hu H; Hu Y; Chen X
Front Immunol; 2018; 9():594. PubMed ID: 29632537
[TBL] [Abstract][Full Text] [Related]
13. [Study of thalidomide on the growth and angiogenesis of ovary cancer SKOV3 transplanted subcutaneously in nude mice].
Li W; Peng ZL; Cao ZY
Zhonghua Fu Chan Ke Za Zhi; 2005 Mar; 40(3):186-9. PubMed ID: 15840315
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth receptor 1 acts as a stress-associated protein in the therapeutic response to thalidomide.
Liu Q; Yin T; Wang G; Guo F; Ou Y; Li Y; Wang Y
Exp Ther Med; 2017 Nov; 14(5):4263-4271. PubMed ID: 29075340
[TBL] [Abstract][Full Text] [Related]
15. TNFR2: Role in Cancer Immunology and Immunotherapy.
Yang Y; Islam MS; Hu Y; Chen X
Immunotargets Ther; 2021; 10():103-122. PubMed ID: 33907692
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study.
Karrow NA; Guo TL; Zhang LX; McCay JA; Musgrove DL; Peachee VL; Germolec DR; White KL
Int Immunopharmacol; 2003 Oct; 3(10-11):1447-56. PubMed ID: 12946441
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Nishikawa H; Koyama S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
[TBL] [Abstract][Full Text] [Related]
18. The modulation of tumor vessel permeability by thalidomide and its impacts on different types of targeted drug delivery systems in a sarcoma mouse model.
Wang D; Fu J; Shi Y; Peng D; Yuan L; He B; Dai W; Zhang H; Wang X; Tian J; Zhang Q
J Control Release; 2016 Sep; 238():186-196. PubMed ID: 27422610
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner.
Bian C; Qin WJ; Zhang CY; Zou GL; Zhu YZ; Chen J; Zhao R; Wang YY; Zhe H
Free Radic Biol Med; 2018 Dec; 129():446-453. PubMed ID: 30339882
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia.
Ma J; Ning YN; Xu M; Hou Y; Wang N; Hou XY; Yu YY; Li H; He WD; Shao LL; Zhou H; Min YN; Liu XG; Shi Y; Qin P; Guo CS; Hou M; Peng J
Blood; 2013 Sep; 122(12):2074-82. PubMed ID: 23926306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
